Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Torrent Pharmaceuticals Ltd

| Q3 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤13th Feb 26

Summary : Torrent Pharma reported strong Q3 FY'26 results with robust growth in key markets, progressing well on the JB Pharma acquisition, and outlining clear growth strategies despite some operational challenges.

Management Perspective positive : Management expressed confidence in healthy performance, double-digit growth, and being 'on track' for acquisitions. They are 'hopeful' for continued high growth and 'optimistic' about U.S. sales targets, despite acknowledging challenges.

Concall Report Analysis & Insights

Business Overview

  1. Q3 FY'26 revenues grew 18% to INR 3,303 crores.
  2. Operating EBITDA increased 19% to INR 1,088 crores, with a 32.9% margin.
  3. Branded markets, comprising 75% of revenue, showed healthy performance.
  4. India business grew 14%, and Brazil grew 27% (10% constant currency).
  5. Acquired 48.8% controlling stake in JB Pharma, consolidating from January 21.
  6. Curatio business achieved 27% growth in Q3 and year-to-date.

Future Growth Prospects

  1. India business is expected to continue outperforming market growth.
  2. Focus on improving market share in key therapies and scaling Curatio business.
  3. Brazil has a strong pipeline of 60 molecules awaiting ANVISA approval.
  4. U.S. business targets $200 million in sales by FY'27 with 5-7 annual launches.
  5. JB acquisition is expected to generate INR 400-450 crores in cost synergies over 2-3 years.

Management Insights

  1. Branded markets are the primary growth driver, contributing 75% of revenues.
  2. JB Pharma acquisition is on track for merger, with SEBI and NCLT approvals pending.
  3. Curatio's strong growth is attributed to increased ad spends and field force expansion.
  4. U.S. growth is driven by new product launches and increased existing contract volumes.
  5. Cost synergies from JB acquisition are projected at INR 400-450 crores over 2-3 years.
  6. JB's EBITDA margin has significant scope for improvement post-integration.

Signs of Skepticism

  1. No clear timeline provided for resolving Germany's supply disruption issues.
  2. Revenue synergies from the JB acquisition are not quantified for the first year.
  3. U.S. sales target of $200 million by FY'27 is described as 'optimistic' and a 'punt'.
  4. Brazilian GLP-1 launch is delayed, and significant price erosion is anticipated.

Risk Factors

  1. Germany business faces ongoing disruption from a 3rd-party supplier's regulatory issues.
  2. Transitioning to an alternative supplier for Germany will take 3-4 quarters.
  3. Brazilian GLP-1 product launch is delayed, with potential for 45-50% price erosion.
  4. Q4 financials may be muted due to initial JB integration changes.
  5. JB's trade generics business may be discontinued or shifted due to strategy misalignment.

Good To Know

  1. India's 14% growth comprises 5.5% volume, 5.8% price, and 2.7% new products.
  2. The average cost of interest for the company is approximately 7.6%.
  3. A hedging loss of INR 45 crores was recorded in other income for the quarter.
  4. Brazil's market growth has slowed to 6-7%, with Torrent targeting 10-15% growth.
  5. Brazil's GLP-1 market is prescription-driven, limiting product substitution.

Key Drivers

  1. JB Pharma acquisition integration.
  2. Strong double-digit growth in India.
  3. Brazil GLP-1 product launches.
  4. U.S. new product pipeline.

Key Analyst Discussions

Competitive Environment

  1. Brazil GLP-1 market expects 45-50% price erosion due to competition.
  2. U.S. growth depends on new launches and competitive landscape.
  3. Brazil market growth slowed, impacting pricing due to competition.

Market Trends & Consumer Behavior

  1. India's IPM growth was 10%, with Torrent outperforming.
  2. Curatio's demand is driven by OTC ad spends and field force expansion.
  3. Brazil's market growth has slowed due to inflation control and interest rates.

Financial Highlights

  1. JB acquisition will be consolidated line-by-line from Q4 FY'26.
  2. India's 14% growth split across volume, price, and new products was clarified.
  3. JB's EBITDA margin is expected to improve towards Torrent's levels.
  4. Net debt at Q3 end was INR 880 crores, with a target net EBITDA of 0.6x by FY'29.

Product Composition

  1. GLP-1 (Semaglutide) launch in Brazil will prioritize Ozempic generics.
  2. Brazil expects 5-6 new product launches, excluding Semaglutide.
  3. JB's trade generics business will be re-evaluated for strategic alignment.

Strategic Considerations

  1. JB acquisition synergies are primarily cost-related, not revenue-focused initially.
  2. International expansion targets Russia, Mexico, and Philippines for $50M markets.
  3. U.S. sales target of $200 million by FY'27 is an optimistic milestone.
Torrent Pharmaceuticals Ltd (TORNTPHARM) Concall Report Analysis & Insights | Dhanarthi